A recent study investigated the short-term effects of an anti-IL-6 treatment (tocilizumab) on bone turnover markers (BMTs) in RA patients, comparing it with TNFi and GCs (methyl-prednisone) (79). Here, IL6 is linked to rheumatoid arthritis.